| Emerald Behavioral Healthcare Llc | |
|
368 White Horse Pike Atco NJ 08004-2235 | |
| (856) 753-5788 | |
| Not Available |
| Full Name | Emerald Behavioral Healthcare Llc |
|---|---|
| Speciality | Clinic/center |
| Location | 368 White Horse Pike, Atco, New Jersey |
| Authorized Official Name and Position | Aaron Kreiswirth (MEMBER) |
| Authorized Official Contact | 6093838668 |
| Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
| Mailing Address | Practice Location Address |
|---|---|
| Emerald Behavioral Healthcare Llc Po Box 285 Clayton NJ 08312-0285 Ph: (609) 383-8668 | Emerald Behavioral Healthcare Llc 368 White Horse Pike Atco NJ 08004-2235 Ph: (856) 753-5788 |
| NPI Number | 1013685593 |
|---|---|
| Provider Enumeration Date | 08/31/2021 |
| Last Update Date | 08/31/2021 |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013685593 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261Q00000X | Clinic/center | (* (Not Available)) | Primary |
News Archive
PDL BioPharma, Inc. today announced that it has entered into a non-exclusive license agreement with Eli Lilly and Company under PDL's Queen et al patents with respect to teplizumab, a humanized anti-CD3 monoclonal antibody, as well as other potential next generation anti-CD3 molecules.
According to researchers, screening for the AIDS virus to include every American at least once and the highest-risk people once a year could prevent more than 80,000 infections over the next 20 years. The team from Yale University in Connecticut and Stanford University in California reported that if treatment for infected people were integrated into such a program, it would prevent an estimated 212,000 new infections.
Heart muscle cells do not normally replicate in adult tissue, but multiply with abandoned during development. This is why the loss of heart muscle after a heart attack is so dire-you can't grow enough new heart muscle to make up for the loss.
A long non-coding RNA (lncRNA) regulates programmed cell death during one of the final stages of red blood cell differentiation, according to Whitehead Institute researchers. This is the first time a lncRNA has been found to play a role in red blood cell development and the first time a lncRNA has been shown to affect programmed cell death.
› Verified 7 days ago